Apogem Capital’s AbbVie ABBV Stock Holding History

Apogem Capital’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,910	Closed	-$206K	–	175
2021 Q3	$206K	Buy	+1,910	New	+$218K	0.13%	174

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Apogem Capital's ABBV Position: Q4 2021 in Review

Apogem Capital sold out of AbbVie (ABBV) in Q4 2021, closing a stake of 1,910 shares — an estimated $206K sold.

Apogem Capital first reported a position in ABBV in Q3 2021 and held it in 1 quarter. The position peaked at $206K in Q3 2021. 2,982 funds tracked by Wall St. Rank hold ABBV as of Q4 2021.

Apogem Capital reported no remaining AbbVie position as of Q4 2021 after selling out during the quarter.
Apogem Capital sold 1,910 AbbVie shares in Q4 2021, an estimated $206K.
Apogem Capital first reported a position in AbbVie in Q3 2021 and held it in 1 quarter.
Apogem Capital's AbbVie position peaked at $206K in Q3 2021.
2,982 funds tracked by Wall St. Rank held AbbVie as of Q4 2021.

Based on Apogem Capital's 13F filing for Q4 2021, filed 14 Feb 2022.